The CDC’s ACIP decided to postpone a vote on recommending Merck’s new pneumococcal vaccine for all adults age 50-64.
But the committee seems to be leaning towards the recommendation versus the current risk-based approach in that age group, because a universal recommendation will improve health equity.
The ACIP wants data on the impact of recommending all pneumococcal vaccines, not just Merck’s newest, universally for people 50-64 before making a decision.
Questions about the length of vaccine protection made the committee’s decision harder.

Merck's Pneumococcal Vaccine Market Expansion Stalled By Ever-Changing, Crowded Field

More from US FDA Performance Tracker